"Efficacy results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson’s disease (P2.8-048)." Neurology
92.15 Supplement
(2019):
P2.8-048.
Web. 25 Feb. 2020.
Advertisement
The most widely read and highly cited peer-reviewed neurology journal
